Biotech Values

[wjlknew]

<Too bad INSM didn't agree to 30% and put this behind them.>

Considering it will be several years before INSM sees over $100 million in net sales, I would say 15% is about twice as good as agreeing to 30%.

<If the injunction were granted, how would INSM survive while awaiting the appeal process to run it's course?>

It's not probable that an injunction will be granted, but INSM would survive the same way it did prior to launching Iplex ... with no royalties to pay. INSM is not a one trick pony.

The fact of the matter is INSM is in a better position now than a year ago, with a promising future.